Patricia Folkins, Melanie Szweras and Nicole LaBerge coauthored the article "Repurposed Drugs in the Fight Against COVID-19" by LexisNexis
September 2, 2020
Patricia Folkins, Melanie Szweras and Nicole LaBerge coauthored the article "Repurposed Drugs in the Fight Against COVID-19" in Risk Management in Canadian Health Care, published by LexisNexis.
Repurposing existing or abandoned drugs is an attractive route to finding a treatment and cure for COVID-19 quickly. To initiate such efforts, the World Health Organization (WHO) has set up a research network with the aim of identifying drug therapies and combinations that could be used to treat COVID-19.1 Such drugs have already undergone safety, efficacy, and toxicity studies for treatment of a different disease. Repurposing drugs presents pharmaceutical companies with new sales and marketing opportunities, is budget conscious, and faster than developing a drug from scratch. Past examples include minoxidil, sildenafil (ViagraTM), and thalidomide.
The Risk Management in Canadian Health Care newsletter is available for purchase here.
This article was first published by Bereskin & Parr LLP on July 7, 2020.